← ANALYST RATINGS · TIPRANKS
Vir Biotechnology (VIR): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $23.00, the highest $30.00, the lowest $18.00. The average is +130.9% from the last price of $9.96.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.00−8.3% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.50 → $11.50−8.0% | Buy | +15.5% | Upgrade | 14.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $11.00−8.3% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 → $11.00−8.3% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $12.00−4.0% | Buy | +20.5% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.00−8.3% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 17:05 | — | |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $22.00 | Buy | +120.9% | Reiterated | 14.10.26on TipRanks 11:35 | −0.8%next day +0.3% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $30.00 | Buy | +201.2% | Reiterated | 08.10.26on TipRanks 05:25 | −3.0%next day +4.6% · 5 days −5.6% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $17.00 | Buy | +70.7% | Reiterated | 29.09.26on TipRanks Sep 30 04:00 | +1.5%next day +5.2% · 5 days +7.0% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $18.00 | Buy | +80.7% | Reiterated | 28.09.26on TipRanks 12:45 | −0.7%next day +1.5% · 5 days +10.9% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $16.00 → $15.00−6.2% | Buy | +50.6% | Reiterated | 07.08.26on TipRanks 06:50 | 0.0%next day +0.8% · 5 days +4.4% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $22.00 | Buy | +120.9% | Reiterated | 06.08.26on TipRanks 08:25 | −3.6%next day 0.0% · 5 days +1.5% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $27.00 → $25.00−7.4% | Buy | +151.0% | Assigned | 06.08.26on TipRanks 07:11 | −3.6%next day 0.0% · 5 days +1.5% | ↗ |
| Phil Nadeau★★★★★★★★★★#1350 · hits 48% · avg +8.7% | TD Cowen | — | Buy | — | Reiterated | 05.08.26on TipRanks Aug 6 06:00 | −0.5%next day −3.6% · 5 days −2.0% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $21.00 | Buy | +110.8% | Reiterated | 06.05.26on TipRanks May 7 07:15 | +1.4%next day −9.6% · 5 days −10.5% | ↗ |
| Sean McCutcheon★★★★★★★★★★#1382 · hits 43% · avg +39.7% | Raymond James | $12.00 → $19.00+58.3% | Buy | +90.8% | Reiterated | 24.02.26on TipRanks 06:15 | +27.0%next day +4.5% · 5 days −5.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Vir Biotechnology
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $21.00 at a price of $11.18 (+87.8%); now: $21.29 at $9.96 (+113.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 11 | 9 | 6 | 6 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.74 (from $-0.95 to $-0.58). Last quarter: $0.47.
Sales
Next quarter’s sales estimate — $1M (from $0M to $3M). Last quarter: $239M.
Best top-analyst consensus in the sector · Healthcare
About Vir Biotechnology
- CEO: Marianne De Backer
- Employees: 367
- 499 Illinois Street, San Francisco, CA, 94158, US
- www.vir.bio
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Data from the stock’s TipRanks forecast page, read 11 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗